| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CK-16; CK16; cytokeratin 16; Cytokeratin-16; FNEPPK; K16; K1C16; K1CP; keratin 16; Keratin-16; KRT16; KRT16A; NEPPK;;Cytokeratin 16 |
| WB Predicted band size | 51 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human Cytokeratin 16 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于Cytokeratin 16(CK16/KRT16)抗体的3篇参考文献及其摘要概括：
1. **文献名称**：*"The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells"*
**作者**：Moll, R., Franke, W.W., Schiller, D.L., et al.
**摘要**：该研究系统分类了人类细胞角蛋白(包括CK16)，发现CK16在特定增生性上皮(如银屑病皮肤、口腔黏膜及某些肿瘤)中异常高表达，提示其与上皮细胞异常增殖相关。
2. **文献名称**：*"Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro"*
**作者**：Leigh, I.M., Navsaria, H., Purkis, P.E., et al.
**摘要**：通过免疫组化分析，发现CK16在银屑病皮损中显著过表达，表明其可作为表皮角质形成细胞过度增殖的分子标志物，并可能与炎症性皮肤疾病相关。
3. **文献名称**：*"Cytokeratin 16 expression in human breast cancer: correlation with prognostic factors and survival"*
**作者**：Paladini, R., Fabris, G., Krams, M., et al.
**摘要**：研究CK16在乳腺癌中的表达模式，发现其与肿瘤侵袭性及不良预后相关，提示CK16抗体可用于乳腺癌组织分型及临床预后评估。
4. **文献名称**：*"Keratin 16 expression in wound healing and epithelial remodeling: a focus on chronic ulcers"*
**作者**：Purkis, P.E., Steel, J.B., Mackenzie, I.C., et al.
**摘要**：探讨CK16在皮肤伤口愈合中的动态表达，发现慢性溃疡组织中CK16持续高表达，可能反映上皮修复障碍及异常角化过程。
---
以上文献覆盖了CK16在皮肤疾病、癌症及组织修复中的功能研究，适用于抗体在病理诊断或机制研究中的应用参考。
Cytokeratin 16 (CK16) is a type I intermediate filament protein encoded by the *KRT16* gene, primarily expressed in stratified epithelial tissues such as the skin, nails, and mucosal surfaces. It plays a structural role in maintaining epithelial integrity and is dynamically regulated during cellular differentiation, wound healing, and stress responses. CK16 is notably upregulated in hyperproliferative or inflamed states, making it a marker of pathological keratinization. Its overexpression is linked to chronic skin disorders like psoriasis, lichen planus, and certain blistering diseases, where abnormal keratinocyte proliferation or dysregulated immune signaling occurs.
In cancer research, CK16 antibodies are used to study its expression in squamous cell carcinomas (e.g., head, neck, or esophageal cancers) and other malignancies, where it may correlate with tumor aggressiveness or metastatic potential. Commercially available CK16 antibodies (e.g., monoclonal clones like EP1607Y) enable detection via immunohistochemistry, immunofluorescence, or immunoblotting, aiding in differential diagnosis and research into epithelial pathophysiology. Recent studies also explore CK16's role in immune modulation, particularly in psoriasis, where it may interact with pro-inflammatory cytokines. Despite its diagnostic and research utility, CK16's precise mechanistic contributions to disease remain under investigation, highlighting its dual role as both a structural component and a mediator of epithelial stress responses.
×
